A new generation of high potency veterinary cancer medications and nutraceuticals for pets

Applying science to discover therapies that significantly improve
and extend pets lives.

How many companion animals are diagnosed with cancer each year?
It is estimated that 70-80 million dogs and 74-96 million cats are owned in the United States.
Every day 10,000 dogs and 6,000 cats are diagnosed with cancer.

Featured Press Releases

June 1, 2017 PetLife Pharmaceuticals Launches New Website
HANCOCK, MD / May 30, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company,” “PetLife”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced its new Website,
View Release

May 30, 2017 PetLife Files for Patent for the Treatment of Cancer for Pets
Combining Chlorotoxin and Plant-based Therapeutics in an Advanced Formulation with New Technology
View Release

PetLife Pharmaceuticals, Inc. (PTLF) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, Vitalzul™, is currently in testing. Vitalzul’s™ active ingredients have been shown to have activity against several different cancer cell lines.

Important Facts to Know

• 1/4 of dogs and 1/5 of cats will develop cancer in their lifetime!
• Cancer is the #1 disease related cause of death in dogs in the US
• Cancer accounts for almost 50% of deaths in pets older than 10 years old
• Conventional treatment can cost SEVERAL thousands of dollars, forcing pet owners to watch their pet slowly deteriorate

New frontier in pet oncological treatment utilizing the venom of the Blue Scorpion

PetLife Pharmaceuticals is introducing a new breakthrough pet cancer drug that is anticipated to begin FDA trials in the upcoming months. The drug is an all-natural compound. The FDA trials are estimated to take approximately 18-24 months. PetLife Pharmaceuticals, Inc. is a publicly traded company. The stock symbol is PTLF on the OTCQB market. PetLife is a new biotech company developing products to address disease in our companion pets.